Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review

Inflammatory Bowel Diseases

Volumn 15, Issue 8, 2009, Pages 1264-1275

  Cassinotti, Andrea ^a   Travis, Simon ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Antibodies; Crohn's disease; Immunogenicity; Infliximab

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE;

B LYMPHOCYTE; BIOTINYLATION; CELLULAR IMMUNITY; CLINICAL DECISION MAKING; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INCIDENCE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; CROHN DISEASE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349512283     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20899     Document Type: Review

References (56)

1. Stange EF, Travis SPL, Vermeire S, et al. European Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis. 2008;2:1-23.
2. Travis SP, Stange EF, Lemann M, et al. European Crohn's and Colitis Organisation. European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55(suppl 1):i16-i35.
3. Breese E, McDonald TT. TNF alpha secreting cells in normal and diseased human intestine. Adv Exp Med Biol. 1995;371:821-824.
4. Braegger CP, Nicholls S, Murch SH, et al. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339:89-91.
5. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther. 2006;23:451-463.
6. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593-1610.
7. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117:761-794.
8. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004;126:402-413.
9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002;359: 1541-1549.
10. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96:722-729.
11. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95:3469-3477.
12. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol. 2000;95:3490-3497.
13. Hanauer SB. Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999;13(suppl 4):16-22.
14. Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis 2001; 7(suppl 1):S17-S22.
15. Han PD, Cohen RD. Managing immunogenic responses to infliximab. Treatment implications for patients with Crohn's disease. Drugs. 2004; 64:1767-1777.
16. Cassinotti A, Ardizzone S, Bianchi Porro G. Adalimumab for the treatment of Crohn's disease. Biologics Targets Ther. 2008;2:763-777.
17. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24:1720-1740.
18. Cassinotti A, Ardizzone S, Bianchi Porro G. Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease. Core Evidence. 2007;2:209-224.
19. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
20. West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008;28:1122-1126.
21. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. New Engl J Med. 2007;357:228-238.
22. Schreiber S, Khaliq-Kareemi M, Lawrence I, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357: 239-250.
23. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921-926.
24. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther. 2001;15:463-473.
25. Schifferli JA, Taylor RP. Physiological and pathological aspects of circulating immune complexes. Kidney Int. 1989;35:993-1003.
26. van der Laken CJ, Voskuyl AE, Roos JC. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis. 2007;66:253-256.
27. Johansson A, Erlandsson A, Eriksson D, et al. Idiotypic-anti-idiotypic complexes and their in vivo metabolism. Cancer. 2002;94:1306-1313.
28. Rojas JR, Taylor RP, Cunningham MR, et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther. 2005;313:578-585.
29. Aarden L, Ruuls SR, Wolbin G. Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement. Curr Opin Immunol. 2008;20:431-435.
30. Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Rheumatol. 2003;30:2315-2318.
31. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
32. Edrees AF, Misra SN, Abdou NI. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol. 2005;23:469-474.
33. Hennig C, Rink L, Fagin U, et al. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods. 2000;235: 71-80.
34. Bendtzen K. Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003;61(suppl 5):S6-10.
35. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005;72:250-256.
36. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008;103:944-948.
37. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor Infliximab. Arthritis Rheum. 2006;54:3782-3789.
38. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology. 2007;46:1828-1834.
39. Pendley C, Schantz A, Wagner C. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther. 2003;5:172-179.
40. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003;124:917-924.
41. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231.
42. Hanauer S, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-543.
43. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
44. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134: 1861-1868.
45. Feagan BG, McDonald J, Ponich T, et al. A randomized trial of methotrexate (MTX) in combination with infliximab (IFX) for the treatment of Crohn's disease (CD) [late-breaking abstract]. Gastroenterology. 2008;134:682c.
46. Colombel JF, Rutgeerts P, Reinish W, et al. SONIC: a randomized double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators and biologic therapy. Gut. 2008;57:(suppl II)-A1.
47. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
48. Wagner C, Olson A, Ford J, et al. Effects of antibodies to infliximab on safety and efficacy of infliximab treatment in patients with Crohn's disease. Gastroenterology. 2002;122(suppl):A-613-A-614.
49. Hanauer SB, Rutgeerts PJ, D'Haens G, et al. Delayed hypersensitivity to infliximab (Remicade) re-infusion after 2-4 year interval without treatment [abstract]. Gastroenterology. 1999;116:A731.
50. Schnitzler F, Fiddler H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single centre cohort. Gut. 2008 (in press).
51. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol. 2002;97:2357-2363.
52. Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther. 2003;17:1451-1457.
53. Mortimore M, Gibson PR, Selby WS, et al. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J. 2001;31:146-150.
54. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo controlled trial. Gastroenterology. 2006;130:1054-1061.
55. Travis S. Infliximab and azathioprine: bridge or parachute? Gastroenterology. 2006;130:1354-1357.
56. Kaplan GG, Hur C, Korzenik J, et al. Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007;26:1509-1520.